{
    "clinical_study": {
        "@rank": "156425", 
        "acronym": "RAPID II", 
        "arm_group": [
            {
                "arm_group_label": "Renal Denervation", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication."
            }, 
            {
                "arm_group_label": "Optimal Medical Therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects randomized to the control arm will be maintained on antihypertensive medications."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a global, multi-center, prospective, randomized, controlled study of the safety and\n      effectiveness of renal denervation with the OneShot Renal Denervation System in patients\n      with uncontrolled hypertension."
        }, 
        "brief_title": "Rapid Renal Sympathetic Denervation for Resistant Hypertension II", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Resistant Hypertension", 
            "Uncontrolled Hypertension", 
            "Renal Artery Ablation"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individual has a systolic blood pressure \u2265 160 mmHg based on an average of three\n             office blood pressure readings.\n\n          -  Stable drug regimen including three or more anti-hypertensive medications including a\n             diuretic\n\n        Exclusion Criteria:\n\n          -  Renal anatomy unsuitable for treatment\n\n          -  Presence of hemodynamically significant valvular heart disease for which reduction of\n             blood pressure would be considered hazardous\n\n          -  Patient has Type I diabetes\n\n          -  Has scheduled or planned surgery within the next 6 months\n\n          -  Individual is pregnant nursing or plans to be pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "253", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939392", 
            "org_study_id": "CP-1003"
        }, 
        "intervention": {
            "arm_group_label": "Renal Denervation", 
            "intervention_name": "Renal Denervation (OneShot\u2122 Renal Denervation System)", 
            "intervention_type": "Device", 
            "other_name": [
                "OneShot Ablation system", 
                "Catheter-based renal denervation"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Resistant hypertension", 
            "Uncontrolled hypertension", 
            "Renal artery ablation"
        ], 
        "lastchanged_date": "September 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy"
                }, 
                "name": "Hospital San Raffaele"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II", 
        "overall_contact": {
            "email": "karen.krygier@covidien.com", 
            "last_name": "Karen Krygier, MBA"
        }, 
        "overall_official": [
            {
                "affiliation": "Park-Krankenhaus Liepzig", 
                "last_name": "Dierk Scheinert, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universita Minano-Bicocca, Ospedale San Gerardo di Monza", 
                "last_name": "Guiseppe Mancia, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Major adverse event (MAE) rate through 30 days post randomization", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Change in office systolic blood pressure (SBP) from baseline to 6 months post-randomization", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acute Procedural Safety", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Chronic procedural safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Reduction in SBP by >10 mmHg at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Changes in office SBP and diastolic blood pressure (DBP) from baseline to follow-up visits", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 24, and 36 months"
            }
        ], 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}